Related references
Note: Only part of the references are listed.Using Exhaled Nitric Oxide and Serum Periostin as a Composite Marker to Identify, Severe/Steroid-Insensitive Asthma
Tadao Nagasaki et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)
Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study
Tomoko Tajiri et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2014)
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Kian Fan Chung et al.
EUROPEAN RESPIRATORY JOURNAL (2014)
Auto-anti-IgE: Naturally occurring IgG anti-IgE antibodies may inhibit allergen-induced basophil activation
Yih-Chih Chan et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Integrating longitudinal information on pulmonary function and inflammation using asthma phenotypes
Tadao Nagasaki et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Prevalence and Clinical Relevance of Allergic Rhinitis in Patients with Classic Asthma and Cough Variant Asthma
Tomoko Tajiri et al.
RESPIRATION (2014)
Development of Assay for Determining Free IgE Levels in Serum from Patients Treated with Omalizumab
Reiko Ito et al.
ALLERGOLOGY INTERNATIONAL (2014)
Serum Periostin: A Novel Biomarker for Asthma Management
Hisako Matsumoto
ALLERGOLOGY INTERNATIONAL (2014)
Omalizumab in Asthma: An Update on Recent Developments
Marc Humbert et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2014)
Exploring the Effects of Omalizumab in Allergic Asthma An Analysis of Biomarkers in the EXTRA Study
Nicola A. Hanania et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects
William Busse et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids
Yoshihiro Kanemitsu et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Assessment of Long-term Omalizumab Treatment in Patients with Severe Allergic Asthma Long-term Omalizumab Treatment in Severe Asthma
Eylem Sercan Ozgur et al.
JOURNAL OF ASTHMA (2013)
The eXpeRience registry: The 'real-world' effectiveness of omalizumab in allergic asthma
G. -J. Braunstahl et al.
RESPIRATORY MEDICINE (2013)
Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients
Guiquan Jia et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Monitoring free serum IgE in severe asthma patients treated with omalizumab
Stephanie Korn et al.
RESPIRATORY MEDICINE (2012)
Long-term omalizumab treatment in severe allergic asthma: The South-Eastern Mediterranean real-life experience
Eleni G. Tzortzaki et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2012)
Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy A Randomized Trial
Nicola A. Hanania et al.
ANNALS OF INTERNAL MEDICINE (2011)
Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE
Philip J. Lowe et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias
M. Okamoto et al.
EUROPEAN RESPIRATORY JOURNAL (2011)
Anti-inflammatory effects of seven years treatment with Omalizumab in severe uncontrolled asthmatics
E. Pace et al.
ALLERGY (2010)
Predicting and evaluating response to omalizumab in patients with severe allergic asthma
J. Bousquet et al.
RESPIRATORY MEDICINE (2007)
Recent asthma exacerbations: A key predictor of future exacerbations
Mary K. Miller et al.
RESPIRATORY MEDICINE (2007)
Periostin: A novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals
Go Takayama et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2006)
ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005
American Thoracic Society et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment):: INNOVATE
M Humbert et al.
ALLERGY (2005)
Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma
ST Holgate et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2004)
Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma
R Djukanovic et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
Omalizumab-induced reductions in mast cell FcεRI expression and function
LA Beck et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2004)
Distinguishing severe asthma phenotypes: Role of age at onset and eosinophilic inflammation
C Miranda et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2004)
Share Paper
